SCHEMBL4833682

SCHEMBL4833682

CC(C)(C)c1ccc(C=NOCCCOc2ccc(CCC(=O)O)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
FFAR1 O14842 3/20 0.49
PPARG P37231 6/20 0.47
PPARA Q07869 4/20 0.47
ALDH1A1 P00352 1/20 0.47
PPARD Q03181 2/20 0.47
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
RECQL P46063 1/20 0.45
S1PR4 O95977 1/20 0.45
S1PR1 P21453 1/20 0.45
S1PR3 Q99500 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
CYP2C19 P33261 1/20 0.45
NR1H4 Q96RI1 2/20 0.45
EPHX2 P34913 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833673 1.00 LMNA (0.50) LMNAL3MBTL1FFAR1PPARGPPARA
SCHEMBL4826489 0.89 ALDH1A1 (0.49) LMNAPPARGPPARAALDH1A1RECQL
SCHEMBL4826482 0.89 ALDH1A1 (0.49) LMNAPPARGPPARAALDH1A1RECQL
SCHEMBL4833649 0.84 ALDH1A1 (0.47) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4828774 0.83 ALDH1A1 (0.50) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4828776 0.83 ALDH1A1 (0.50) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4828909 0.82 ALDH1A1 (0.45) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4828811 0.81 LMNA (0.50) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4833687 0.79 ALDH1A1 (0.43) LMNAL3MBTL1PPARGPPARAALDH1A1
SCHEMBL4833683 0.79 ALDH1A1 (0.43) LMNAL3MBTL1PPARGPPARAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US claimed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP claimed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO claimed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US claimed
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 LMNA 2902/4885L3MBTL1 2258/4885FFAR1 3149/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 LMNA 2783/4885L3MBTL1 2151/4885FFAR1 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.